EUVIMEDEUVIMED entdecken
Vergleichsstudie

Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells

Yandy Marx Castillo-Aleman iD, Carlos Agustin Villegas-Valverde iD, Antonio Alfonso Bencomo-Hernandez iD, Shinnette Lumame iD, Charisma Castelo iD, Jay Mary Rose-Roque iD, Marlene Cato iD, Nameer Al-Saadawi iD, Mohamed Ibrahim Abu-Haleeqa iD, Aseel Suleiman Alsaid iD, Sakher Ahmad Obeidat iD, Mansi Sachdev iD und 5 weitere

Journal of Clinical Apheresis · 2026-04 · 41 (2)

DOI: 10.1002/jca.70118 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Clinical Apheresis, online erschienen am 27.03.2026. Verfasst von Yandy Marx Castillo-Aleman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, UAE. Hauptthemen laut MEDLINE: Heparin, Anticoagulants, Citric Acid, Blood Component Removal. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Successful hematopoietic stem cell transplantation relies on the collection of a sufficient number of CD34 + hematopoietic progenitor cells (HPCs). While acid citrate dextrose solution A (ACD‐A) is a common anticoagulant (AC) for HPC apheresis [HPC(A)], recent evidence suggests that concomitant heparin may enhance intra‐apheresis recruitment (IAR) of CD34 + cells and improve collection efficiency. This study aimed to compare citrate‐only and citrate–heparin protocols in routine HPC(A) procedures, with a focus on their effects on IAR and efficiency outcomes. A retrospective analysis was performed on 266 HPC(As) from 193 apheresis donors in autologous and allogeneic settings. Donor demographics, procedural parameters, and collection outcomes were compared between the ACD‐A–only and ACD‐A plus heparin protocols. The study endpoints included apheresis yield (AY/kg), collection efficiencies (CE 1 , CE 2 , and cruCE), recruitment ratio (RR), and performance ratio (PR). Statistical analyses included Mann–Whitney U tests, effect sizes, and partial least squares (PLS) regression. Heparinized procedures demonstrated higher processed total blood volume ratios, lower AC volumes, and superior outcomes across CE 1 (83.8% vs. 72.5%, p = 0.00027), CE 2 (70.8% vs. 64.2%, p = 0.0055), cruCE (77.0% vs. 72.4%, p < 0.0001), RR (2.3 vs. 1.7, p < 0.0001), PR (239.3% vs. 208.2%, p < 0.0001), and AY/kg (6.75 vs. 5.23 × 10 6 CD34 + cells/kg, p = 0.0025). The effect size and PLS analyses confirmed the contribution of heparin as an adjunct AC enhancing multiple apheresis outcomes. In summary, citrate–heparin anticoagulation was found to be a feasible strategy that improved key collection efficiency and IAR metrics during HPC(A).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HeparinAnticoagulantsCitric AcidBlood Component RemovalHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHumansAntigens, CD34FemaleRetrospective StudiesMaleAdultMiddle AgedCitratesGlucose

Stichwörter der Autor:innen

anticoagulantscitratehematopoietic stem cell mobilizationheparinleukapheresis

Substanzen

HeparinAnticoagulantsCitric AcidAntigens, CD34acid citrate dextroseCitratesGlucose

Autor:innen und Institutionen

  • Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, UAE.
  • Yas Clinic Khalifa City (YCKC) Hospital, Abu Dhabi, UAE.
  • United Arab Emirates University (UAEU), Abu Dhabi, UAE.

ORCID-Profile: Yandy Marx Castillo-Aleman, Carlos Agustin Villegas-Valverde, Antonio Alfonso Bencomo-Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose-Roque, Marlene Cato, Nameer Al-Saadawi, Mohamed Ibrahim Abu-Haleeqa, Aseel Suleiman Alsaid, Sakher Ahmad Obeidat, Mansi Sachdev, Jayakumar David Dennison, Inas El-Najjar, Rene Antonio Rivero-Jimenez, Yendry Ventura-Carmenate, Fatema Mohammed Al-Kaabi

Zitieren

APA

Castillo-Aleman, Y. M., Villegas-Valverde, C. A., Bencomo-Hernandez, A. A., Lumame, S., Castelo, C., Rose-Roque, J. M., Cato, M., Al-Saadawi, N., Abu-Haleeqa, M. I., Alsaid, A. S., Obeidat, S. A., Sachdev, M., Dennison, J. D., El-Najjar, I., Rivero-Jimenez, R. A., Ventura-Carmenate, Y., & Al-Kaabi, F. M. (2026). Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells. Journal of Clinical Apheresis, 41(2). https://doi.org/10.1002/jca.70118

Vancouver

Castillo-Aleman YM, Villegas-Valverde CA, Bencomo-Hernandez AA, Lumame S, Castelo C, Rose-Roque JM, et al. Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells. Journal of Clinical Apheresis. 2026;41(2). doi:10.1002/jca.70118

BibTeX
@article{CastilloAleman2026,
  author = {Castillo-Aleman, Yandy Marx and Villegas-Valverde, Carlos Agustin and Bencomo-Hernandez, Antonio Alfonso and Lumame, Shinnette and Castelo, Charisma and Rose-Roque, Jay Mary and Cato, Marlene and Al-Saadawi, Nameer and Abu-Haleeqa, Mohamed Ibrahim and Alsaid, Aseel Suleiman and Obeidat, Sakher Ahmad and Sachdev, Mansi and Dennison, Jayakumar David and El-Najjar, Inas and Rivero-Jimenez, Rene Antonio and Ventura-Carmenate, Yendry and Al-Kaabi, Fatema Mohammed},
  title = {Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  volume = {41},
  number = {2},
  doi = {10.1002/jca.70118}
}
Kostenlos starten →